|
1
|
Burke RE and O'Malley K: Axon degeneration
in Parkinson's disease. Exp Neurol. 246:72–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung UJ, Leem E and Kim SR: Naringin: a
protector of the nigrostriatal dopaminergic projection. Exp
Neurobiol. 23:124–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leem E, Nam JH, Jeon MT, et al: Naringin
protects the nigrostriatal dopaminergic projection through
induction of GDNF in a neurotoxin model of Parkinson's disease. J
Nutr Biochem. 25:801–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Savitt JM, Dawson VL and Dawson TM:
Diagnosis and treatment of Parkinson disease: molecules to
medicine. J Clin Invest. 116:1744–1754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartus RT, Weinberg MS and Samulski RJ:
Parkinson's disease gene therapy: success by design meets failure
by efficacy. Mol Ther. 22:487–497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coune PG, Schneider BL and Aebischer P:
Parkinson's disease: gene therapies. Cold Spring Harb Perspect Med.
2:a0094312012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren X, Zhang T, Gong X, Hu G, Ding W and
Wang X: AAV2-mediated striatum delivery of human CDNF prevents the
deterioration of midbrain dopamine neurons in a 6-hydroxydopamine
induced parkinsonian rat model. Exp Neurol. 248:148–156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SR, Kareva T, Yarygina O, Kholodilov N
and Burke RE: AAV transduction of dopamine neurons with
constitutively active Rheb protects from neurodegeneration and
mediates axon regrowth. Mol Ther. 20:275–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SR, Chen X, Oo TF, Kareva T, Yarygina
O, Wang C, During M, Kholodilov N and Burke RE: Dopaminergic
pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann
Neurol. 70:110–120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allen SJ, Watson JJ, Shoemark DK, Barua NU
and Patel NK: GDNF, NGF and BDNF as therapeutic options for
neurodegeneration. Pharmacol Ther. 138:155–175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin LF, Doherty DH, Lile JD, Bektesh S and
Collins F: GDNF: a glial cell line-derived neurotrophic factor for
midbrain dopaminergic neurons. Science. 260:1130–1132. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Manfredsson FP, Okun MS and Mandel RJ:
Gene therapy for neurological disorders: challenges and future
prospects for the use of growth factors for the treatment of
Parkinson's disease. Curr Gene Ther. 9:375–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegel GJ and Chauhan NB: Neurotrophic
factors in Alzheimer's and Parkinson's disease brain. Brain Res
Brain Res Rev. 33:199–227. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Howells DW, Porritt MJ, Wong JY, Batchelor
PE, Kalnins R, Hughes AJ and Donnan GA: Reduced BDNF mRNA
expression in the Parkinson's disease substantia nigra. Exp Neurol.
166:127–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Studer L, Spenger C, Seiler RW, Othberg A,
Lindvall O and Odin P: Effects of brain-derived neurotrophic factor
on neuronal structure of dopaminergic neurons in dissociated
cultures of human fetal mesencephalon. Exp Brain Res. 108:328–336.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pochon NA, Menoud A, Tseng JL, Zurn AD and
Aebischer P: Neuronal GDNF expression in the adult rat nervous
system identified by in situ hybridization. Eur J Neurosci.
9:463–471. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seroogy KB, Lundgren KH, Tran TM, Guthrie
KM, Isackson PJ and Gall CM: Dopaminergic neurons in rat ventral
midbrain express brain-derived neurotrophic factor and
neurotrophin-3 mRNAs. J Comp Neurol. 342:321–334. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hyman C, Hofer M, Barde YA, Juhasz M,
Yancopoulos GD, Squinto SP and Lindsay RM: BDNF is a neurotrophic
factor for dopaminergic neurons of the substantia nigra. Nature.
350:230–232. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chauhan NB, Siegel GJ and Lee JM:
Depletion of glial cell line-derived neurotrophic factor in
substantia nigra neurons of Parkinson's disease brain. J Chem
Neuroanat. 21:277–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nam JH, Leem E, Jeon MT, et al: Induction
of GDNF and BDNF by hRheb(S16H) transduction of SNpc neurons:
neuroprotective mechanisms of hRheb(S16H) in a model of Parkinson's
disease. Mol Neurobiol. May 25–2014.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aron L and Klein R: Repairing the
parkinsonian brain with neurotrophic factors. Trends Neurosci.
34:88–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kholodilov N, Kim SR, Yarygina O, Kareva
T, Cho JW, Baohan A and Burke RE: Glial cell line-derived
neurotrophic factor receptor-α1 expressed in striatum in trans
regulates development and injury response of dopamine neurons of
the substantia nigra. J Neurochem. 116:486–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Creedon DJ, Tansey MG, Baloh RH, Osborne
PA, Lampe PA, Fahrner TJ, Heuckeroth RO, Milbrandt J and Johnson EM
Jr: Neurturin shares receptors and signal transduction pathways
with glial cell line-derived neurotrophic factor in sympathetic
neurons. Proc Natl Acad Sci USA. 94:7018–7023. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Selvaraj S, Sun Y, Watt JA, Wang S, Lei S,
Birnbaumer L and Singh BB: Neurotoxin-induced ER stress in mouse
dopaminergic neurons involves downregulation of TRPC1 and
inhibition of AKT/mTOR signaling. J Clin Invest. 122:1354–1367.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brunet A, Datta SR and Greenberg ME:
Transcription-dependent and -independent control of neuronal
survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol.
11:297–305. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang N, El-Hayek YH, Gomez E and Wan Q:
Phosphatase PTEN in neuronal injury and brain disorders. Trends
Neurosci. 30:581–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karassek S, Berghaus C, Schwarten M, et
al: Ras homolog enriched in brain (Rheb) enhances apoptotic
signaling. J Biol Chem. 285:33979–33991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan L, Findlay GM, Jones R, Procter J, Cao
Y and Lamb RF: Hyperactivation of mammalian target of rapamycin
(mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J
Biol Chem. 281:19793–19797. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pascual A, Hidalgo-Figueroa M, Piruat JI,
Pintado CO, Gomez-Diaz R and Lopez-Barneo J: Absolute requirement
of GDNF for adult catecholaminergic neuron survival. Nat Neurosci.
11:755–761. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Porritt MJ, Batchelor PE and Howells DW:
Inhibiting BDNF expression by antisense oligonucleotide infusion
causes loss of nigral dopaminergic neurons. Exp Neurol.
192:226–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nutt JG, Burchiel KJ, Comella CL, et al:
Randomized, double-blind trial of glial cell line-derived
neurotrophic factor (GDNF) in PD. Neurology. 60:69–73. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peterson AL and Nutt JG: Treatment of
Parkinson's disease with trophic factors. Neurotherapeutics.
5:270–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
